Severe Fatigue in Stem Cell Transplantation
关键词
抽象
描述
Fatigue is the most complained side effect that may last for months or even years after treatment ends in patients with cancer. Cancer-related fatigue is described as 'a distressing, persistent, subjective sense of physical, emotional and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning'. The cancer-related fatigue observed in 80% of cancer patients received chemotherapy and/or radiotherapy, yet underlying mechanism of cancer-related fatigue is not still clearly explained.
Hematological malignancy itself and its treatments including chemotherapy, radiotherapy, surgery, medical treatment and/or allogeneic or autologous hematopoietic stem cell transplantation cause lots of early and late adverse effects such as appetite loss, nausea and vomiting, diarrhea, fatigue, sleep disturbance, pain, cardiopulmonary and neuromuscular deconditioning, impairments in mobility, muscle weakness and increased risk of fall.
Hematopoietic stem cells collected from bone marrow, peripheral blood or umbilical cord blood of healthy donors are infused into allogeneic hematopoietic stem cell transplantation (allogeneic-HSCT) recipients with hematological malignancy. Allogeneic-HSCT is highly associated with transplant-related mortality, morbidity, graft-versus host disease and another various complications. Because of the above-mentioned risks, recipients and their caregivers are required to remain close to transplant center in the acute phase of transplantation, approximately 100 days. As a consequence, hematopoietic stem cell transplantation has a negative impact on quality of life in recipients and their caregivers who report fatigue, sleep and sexual problems and emotional distress. Especially fatigue is a destructive symptom for recipients, exists before hematopoietic stem cell transplantation and further deteriorates during the first three weeks after hematopoietic stem cell transplantation. Moreover baseline fatigue severity continues until one year after hematopoietic stem cell transplantation.
Although fatigue has been one of the most intensely experienced symptoms by allogeneic-HSCT recipients, no study has compared pulmonary functions, albumin-hemoglobin-white blood cell levels, dyspnea, respiratory and peripheral muscle strength, submaximal exercise capacity, depression and quality of life between severe-fatigued and non-severe-fatigued allogeneic-HSCT recipients, yet. Therefore investigators aimed to compare the effects of severe fatigue on aforementioned outcomes in recipients.
日期
| 最后验证: | 02/28/2018 |
| 首次提交: | 02/21/2018 |
| 提交的预估入学人数: | 02/21/2018 |
| 首次发布: | 02/27/2018 |
| 上次提交的更新: | 03/07/2018 |
| 最近更新发布: | 03/11/2018 |
| 实际学习开始日期: | 02/29/2012 |
| 预计主要完成日期: | 07/31/2017 |
| 预计完成日期: | 11/30/2017 |
状况或疾病
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Group 1: severe-fatigued recipients These recipients had Fatigue Severity Scale score ≥36. All recipients evaluated with similar methods. Meaurements were Pulmonary function tests, Respiratory muscle strength, Peripheral muscle strength, Functional exercise capacity, Dyspnea, Fatigue, Depression and Quality of life. | |
| Group 2: non-severe-fatigued recipients These recipients had Fatigue Severity Scale score <36. All recipients evaluated with similar methods. Meaurements were Pulmonary function tests, Respiratory muscle strength, Peripheral muscle strength, Functional exercise capacity, Dyspnea, Fatigue, Depression and Quality of life. |
资格标准
| 有资格学习的年龄 | 18 Years 至 18 Years |
| 有资格学习的性别 | All |
| 取样方式 | Non-Probability Sample |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: - being an hematopoietic stem cell transplantation recipient during the intermediate/late post-transplant phase (>100 days), - 18-65 years of age - under standard medications. Exclusion Criteria: - having a cognitive disorder, - orthopedic or neurological disease with a potential to affect functional capacity, - comorbidities such as asthma, chronic obstructive pulmonary disease (COPD), acute infections or pneumonia, - problems which may prevent training such as visual problems and mucositis - having metastasis to any region (bone etc.) - having acute hemorrhage in the intracranial and / or lung and other areas - having any contraindication to exercise training |
结果
主要结果指标
1. Peripheral muscle strength [First day]
次要成果指标
1. 6-minute walking test [First day]
2. Respiratory muscle strength [First day]
3. Pulmonary function test [First day]
4. Fatigue Severity Scale [First day]
5. Modified Medical Research Council Dyspnea scale (MMRC) [First day]
6. Beck Depression Inventory-II (Turkish version) [First day]
7. European Organization for Research and Treatment of Cancer QOL Questionnaire (EORTCQOL) [First day]
